Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.21−0.00 (-1.83%)
Close on Nov 13, 2026Market cap $15.48MP/E –Yield –
Acumen Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Acumen Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $85.93M, down 27.7% year over year. For fiscal 2025 it was $104.89M, up 11.8% from the year before. The highest annual figure on record is $104.89M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.89M | +11.8% |
| FY2024 | Dec 31, 2024 | $93.80M | +121.7% |
| FY2023 | Dec 31, 2023 | $42.32M | +30.8% |
| FY2022 | Dec 31, 2022 | $32.36M | +163.0% |
| FY2021 | Dec 31, 2021 | $12.31M | +53.9% |
| FY2020 | Dec 31, 2020 | $8.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $21.11M | -3.9% |
| Q2 FY2026 | Jun 30, 2026 | $27.81M | -25.1% |
| Q1 FY2026 | Mar 31, 2026 | $16.48M | -34.8% |
| Q4 FY2025 | Dec 31, 2025 | $20.53M | -40.6% |
| Q3 FY2025 | Sep 30, 2025 | $21.97M | -19.4% |
| Q2 FY2025 | Jun 30, 2025 | $37.13M | +90.1% |
| Q1 FY2025 | Mar 31, 2025 | $25.27M | +103.0% |
| Q4 FY2024 | Dec 31, 2024 | $34.57M | +160.1% |
| Q3 FY2024 | Sep 30, 2024 | $27.25M | +143.7% |
| Q2 FY2024 | Jun 30, 2024 | $19.53M | +113.9% |
| Q1 FY2024 | Mar 31, 2024 | $12.45M | +42.9% |
| Q4 FY2023 | Dec 31, 2023 | $13.29M | +23.7% |
| Q3 FY2023 | Sep 30, 2023 | $11.18M | +34.5% |
| Q2 FY2023 | Jun 30, 2023 | $9.13M | +24.8% |
| Q1 FY2023 | Mar 31, 2023 | $8.71M | +45.6% |
| Q4 FY2022 | Dec 31, 2022 | $10.75M | +89.4% |
| Q3 FY2022 | Sep 30, 2022 | $8.31M | +361.6% |
| Q2 FY2022 | Jun 30, 2022 | $7.32M | +224.8% |
| Q1 FY2022 | Mar 31, 2022 | $5.99M | +132.2% |
| Q4 FY2021 | Dec 31, 2021 | $5.67M | +452.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.80M | -39.9% |
| Q2 FY2021 | Jun 30, 2021 | $2.25M | +17.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.58M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.03M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.99M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.93M | – |
See a number that looks wrong?